Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 30:2021:7591141.
doi: 10.1155/2021/7591141. eCollection 2021.

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease

Panu Wetwittayakhlang  1   2 , Farah Albader  3 , Petra A Golovics  1   4 , Gustavo Drügg Hahn  1   5 , Talat Bessissow  1 , Alain Bitton  1 , Waqqas Afif  1 , Gary Wild  1 , Peter L Lakatos  1   6
Affiliations

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease

Panu Wetwittayakhlang et al. Can J Gastroenterol Hepatol. .

Abstract

Background and aims: The impact of COVID-19 has been of great concern in patients with inflammatory bowel disease (IBD) worldwide, including an increased risk of severe outcomes and/or possible flare of IBD. This study aims to evaluate prevalence, outcomes, the impact of COVID-19 in patients with IBD, and risk factors associated with severe COVID-19 or flare of IBD activity.

Methods: A consecutive cohort of IBD patients who were diagnosed with COVID-19 infection and followed up at the McGill University Health Care Centre was obtained between March 1, 2020, and April 30, 2021. Demographics, comorbidities, IBD (type, treatments, pre- and post-COVID-19 clinical activity, biomarkers, and endoscopic activity), and COVID-19-related outcomes (pneumonia, hospitalization, death, and flare of IBD disease) were analyzed.

Results: A cohort of 3,516 IBD patients was included. 82 patients (2.3%) were diagnosed with COVID-19 infection (median age: 39.0 (IQR 27.8-48.0), 77% with Crohn's disease, 50% were female). The prevalence of COVID-19 infection in IBD patients was significantly lower compared to the general population in Canada and Quebec (3.5% versus 4.3%, p < 0.001). Severe COVID-19 occurred in 6 patients (7.3%); 2 patients (2.4%) died. A flare of IBD post-COVID-19 infection was reported in 8 patients (9.8%) within 3 months. Biologic therapy was held during active COVID-19 infection in 37% of patients. Age ≥55 years (odds ratio (OR): 11.1, 95% CI: 1.8-68.0), systemic corticosteroid use (OR: 4.6, 95% CI: 0.7-30.1), active IBD (OR: 3.8, 95% CI: 0.7-20.8), and comorbidity (OR: 4.9, 95% CI: 0.8-28.6) were factors associated with severe COVID-19. After initial infection, 61% of IBD patients received COVID-19 vaccinations.

Conclusion: The prevalence of COVID-19 infection among patients with IBD was lower than that in the general population in Canada. Severe COVID-19, mortality, and flare of IBD were relatively rare, while a large proportion of patients received COVID-19 vaccination. Older age, comorbidities, active IBD disease, and systemic corticosteroid, but not immunosuppressive or biological therapy, were associated with severe COVID-19 infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Guan W.-J., Ni Z.-Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine . 2020;382(18):1708–1720. doi: 10.1056/nejmoa2002032. - DOI - PMC - PubMed
    1. Kim L., Garg S., O’Halloran A., et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-Associated hospitalization surveillance network (COVID-NET) Clinical Infectious Diseases . 2021;72(9):e206–e214. doi: 10.1093/cid/ciaa1012. - DOI - PMC - PubMed
    1. Grasselli G., Greco M., Zanella A., et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in lombardy, Italy. JAMA internal medicine . 2020;180:1345–1355. doi: 10.1001/jamainternmed.2020.3539. - DOI - PMC - PubMed
    1. Bitton A., Vutcovici M., Sewitch M., Suissa S., Brassard P. Mortality trends in Crohnʼs disease and ulcerative colitis. Inflammatory Bowel Diseases . 2016;22(2):416–423. doi: 10.1097/mib.0000000000000608. - DOI - PubMed
    1. Jussila A., Virta L. J., Pukkala E., Färkkilä M. A. Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. Journal of Crohn’s and Colitis . 2014;8(9):1088–1096. doi: 10.1016/j.crohns.2014.02.015. - DOI - PubMed

Substances